Clinical trials · New York, NY
Idiopathic Pulmonary Fibrosis clinical trials in New York
We’re tracking 11 recruiting idiopathic pulmonary fibrosis studies with a site in or near New York — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07036523RecruitingPhase 2
Study of BI 765423 for people with Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
New York, New YorkAges 40 years+ - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
New York, New YorkAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
New York, New YorkAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
New York, New YorkAges 40 years+ - NCT06238622RecruitingPhase 3
Long-term nerandomilast for pulmonary fibrosis follow-up
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
New York, New YorkAges 18 years+ - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
New York, New YorkAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
New York, New YorkAges 21 years+ - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
New York, New YorkAges 40 years+ - NCT05571059RecruitingPhase 2
Ifetroban pills for idiopathic pulmonary fibrosis
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
New York, New YorkAges 40 years+ - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
New York, New YorkAges 40 years+
Hear when a new Idiopathic Pulmonary Fibrosis trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Idiopathic Pulmonary Fibrosis trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting idiopathic pulmonary fibrosis studies listed above.
- Weill Cornell Medicine · 5 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Columbia University Irving Medical Center · 2 studies
- NewYork-Presbyterian Hospital · 2 studies
- Montefiore Medical Center
- Northern Westchester Hospital
- Northwell Health
- NYU Langone Health
What taking part in a idiopathic pulmonary fibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting idiopathic pulmonary fibrosis studies in New York.
Common questions
- Are there idiopathic pulmonary fibrosis clinical trials near New York?
- Yes. We're currently tracking 11 recruiting idiopathic pulmonary fibrosis studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a idiopathic pulmonary fibrosis study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New idiopathic pulmonary fibrosis studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.